期刊
IN VIVO
卷 35, 期 1, 页码 61-68出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/invivo.12232
关键词
Anti-PCSK9; statin intolerance; evolocumab; alirocumab; hypercholesterolemia
Statin intolerance refers to the inability of a patient to tolerate statin therapy, leading to high LDL-C levels and increased cardiovascular risk. PCSK9 inhibitors have shown to be effective in lowering LDL-C levels by up to 70% in statin-intolerant patients, making it a promising treatment option for these individuals.
Background: Statin intolerance refers to the inability of a patient to tolerate statin therapy, presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous patients are not treated with suitable statinbased therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDLC) is not achieved, resulting in patients at a high risk for cardiovascular events, requiring an alternative lipidlowering treatment. Common treatments manage to reduce the LDL-C level by up to 20%. Recently, new alternative treatment options have been proved to lower the LDL-C level by up to 70%. These treatment strategies are based on human monoclonal antibodies against protein convertase subtilisin/kexin 9 (PCSK9). Materials and Methods: Herein, we review the efficiency of anti-PCSK9 in treatment of hypercholesterolemic patients with statin intolerance. We focused on the use of PCSK9 inhibitors in statin-intolerant patients and we estimated the clinical results concerning the reduction of the mean LDL-C concentration and the side effects that were observed. Results: In the majority of cases, treatment strategy based on PCSK9 was successful and achieved the end-points. Conclusion: PCSK9 inhibition can be considered as a treatment of option for lipid-lowering in statin-intolerant patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据